source
- Eli Lilly to buy psychedelics biotech AtaiBeckley for $2.8 billion, adding late-stage depression drugEli Lilly announced it will acquire New York‑based biotech AtaiBeckley in a transaction valued at about $2.8 billion. The agreement sets the purchase price at $6.75 per share, a 26 % premium to At…
- Merck's Lipfendra pill receives FDA approval as first oral PCSK9 cholesterol treatmentThe U.S. Food and Drug Administration approved Lipfendra, an oral medication from Merck that lowers low density lipoprotein cholesterol. The drug blocks the PCSK9 protein, making it the first pill…